Pathologic complete response to pralsetinib in stage IV RET-positive non-small cell lung cancer: A case report

Neoadjuvant therapy with tyrosine kinase inhibitors has been proposed as a feasible approach for downstaging potential resectable non-small cell lung cancer (NSCLC). Pralsetinib is a paradigm of precision medicine for cancers driven by mutant RET (rearranged during transfection). In this case, we re...

Full description

Bibliographic Details

Published in:	Respiratory Medicine Case Reports
Main Authors:	Xinxin Chen, Guoxin Wang, Jianfeng Zhang, Wei Bao, Jun Cai, Jing Guo, Tangfeng Lv, Mingxiang Ye
Format:	Article
Language:	English
Published:	Elsevier 2025-01-01
Subjects:	NSCLC RET Pralsetinib Tumor downstaging pCR
Online Access:	http://www.sciencedirect.com/science/article/pii/S221300712500022X